NCT06310343Completed
ADAs to Alemtuzumab
Impact of Anti-drug Antibodies to Alemtuzumab in Multiple Sclerosis
Source: ClinicalTrials.gov · Last updated 30 Oct 2026
Brief summary (registry, in English)
The main aim is to quantify the changes in alemtuzumab antibody-anti-alemtuzumab over a 24 months period
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 15 (actual)
- First submitted
- 7 Mar 2024
- Start date
- Jul 2022
- Primary completion date
- Oct 2025
- Lead sponsor
- Queen Mary University of London
- Diseases
- Multiple sclerosis
- NCT number
- NCT06310343
What you commit to
- Study type: Observational
- Participants enrolled: 15
- From Jul 2022 to the primary completion date, Oct 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Lab values
- Those unable to comply with study requirements, including frequency of visits. Abnormal baseline investigations (WBC\<3 x 10\*9/l, lymphocytes \<1.0 x 10\*9/l, neutrophil count \<1.5 x 10\*9/l, platelet count \<100 x 10\*9/l, haemoglobin \<110 g/l, LFT \>/3x upper limit of normal of site reference ranges, potassium \<2.8 mmol/l or \>5.5 mmol/l, sodium /,125 mmol/l, creatinine \>130 umol/l).
Other
- Ineligible for alemtuzumab under NHS England prescribing guidelines.
Who the study is looking for
- Patients with RRMS who are being treated with alemtuzumab at Barts Health NHS Trust will be approached to participate in the study.
- Patients must be willing and able to undergo blood tests.
Age in the registry: 18 years to 55 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Barts Health NHS Trust Coordinator of this site? Confirm its status | London | United Kingdom | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.